Neurologic Involvement in COVID-19: Cause or Coincidence? A Neuroimaging Perspective

References

1. 1.↵
   1. Pérez CA

   . Looking ahead: the risk of neurologic complications due to COVID-19. Neurology Clinical Practice April 9, 2020; https://cp.neurology.org/content/early/2020/04/08/CPJ.0000000000000836. Accessed April 15, 2020
2. 2.↵
   1. Li Y,
   2. Bai W,
   3. Hashikawa T

   . The neuroinvasive potential of SARS‐CoV2 may be at least partially responsible for the respiratory failure of COVID‐19 patients. J Med Virol 2020 Feb 27. [Epub ahead of print] doi:10.1002/jmv.25728 pmid:32104915

   CrossRefPubMed
3. 3.↵
   1. Wu Y,
   2. Xu X,
   3. Chen Z, et al

   . Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 2020 Mar 30. [Epub ahead of print] doi:10.1016/j.bbi.2020.03.031 pmid:32240762

   CrossRefPubMed
4. 4.↵
   1. Baig AM,
   2. Khaleeq A,
   3. Ali U, et al

   . Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020;11:995–98 doi:10.1021/acschemneuro.0c00122 pmid:32167747

   CrossRefPubMed
5. 5.↵
   1. Mao L,
   2. Jin H,
   3. Wang M, et al

   . Neurologic manifestations of hospitalized patients with coronavirus disease in Wuhan, China. JAMA Neurol 2020 Apr 10. [Epub ahead of print] doi:10.1001/jamaneurol.2020.1127 pmid:32275288

   CrossRefPubMed
6. 6.↵
   1. Moriguchi T,
   2. Harii N,
   3. Goto J, et al

   . A first case of meningitis/encephalitis associated with SARS-coronavirus-2. Int J Infect Dis 2020;94:55–58 doi:10.1016/j.ijid.2020.03.062 pmid:32251791

   CrossRefPubMed
7. 7.↵
   1. Asadi-Pooya AA,
   2. Simani L

   . Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 2020;413:116832 doi:10.1016/j.jns.2020.116832 pmid:32299017

   CrossRefPubMed
8. 8.↵
   1. Zhou F,
   2. Yu T,
   3. Du R, et al

   . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62 doi:10.1016/S0140-6736(20)30566-3 pmid:32171076

   CrossRefPubMed
9. 9.↵
   1. Tang N,
   2. Bai H,
   3. Chen X, et al

   . Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094–99 doi:10.1111/jth.14817 pmid:32220112

   CrossRefPubMed
10. 10.↵
    1. Zhao H,
    2. Shen D,
    3. Zhou H, et al

    . Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 2020;19:383–84 doi:10.1016/S1474-4422(20)30109-5 pmid:32246917

    CrossRefPubMed
11. 11.↵
    1. Toscano G,
    2. Palmerini F,
    3. Ravaglia S, et al

    . Guillain–Barré syndrome associated with SARS-CoV-2. N Engl J Med 2020 Apr 17. [Epub ahead of print] doi:10.1056/NEJMc2009191 pmid:32302082

    CrossRefPubMed
12. 12.↵
    1. Poyiadji N,
    2. Shahin G,
    3. Noujaim D, et al

    . COVID-19–associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020 Mar 31. [Epub ahead of print] doi:10.1148/radiol.2020201187 pmid:32228363

    CrossRefPubMed
13. 13.↵
    1. Helms J,
    2. Kremer S,
    3. Merdji H, et al

    . Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020 Apr 15. [Epub ahead of print] doi:10.1056/NEJMc2008597 pmid:32294339

    CrossRefPubMed
14. 14.↵
    1. Giacomelli A,
    2. Pezzati L,
    3. Conti F, et al

    . Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. Clin Infect Dis 2020 Mar 26. [Epub ahead of print] doi:10.1093/cid/ciaa330 pmid:32215618

    CrossRefPubMed
15. 15.↵
    1. Klok FA,
    2. Kruip M,
    3. van der Meer NJ, et al

    . Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020 Apr 10. [Epub ahead of print] doi:10.1016/j.thromres.2020.04.013 pmid:32291094

    CrossRefPubMed
16. 16.↵
    1. Li Y,
    2. Wang M,
    3. Zhou Y, et al

    . Acute cerebrovascular disease following COVID-19: a single center: retrospective, observational study. SSRN Electron Journal January 2020. researchgate.net/publication/340154622_Acute_Cerebrovascular_Disease_Following_COVID-19_A_Single_Center_Retrospective_Observational_Study. Accessed April 15, 2020
17. 17.↵
    1. Lauer SA,
    2. Grantz KH,
    3. Bi Q, et al

    . The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020;172:577–82 doi:10.7326/M20-0504 pmid:32150748

    CrossRefPubMed
18. 18.↵
    1. Brann DH,
    2. Tsukahara T,
    3. Weinreb C, et al

    . Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients. bioRxiv March 28, 2020. https://www.biorxiv.org/content/10.1101/2020.03.25.009084v1. Accessed April 16, 2020
19. 19.↵
    1. Hahn AF

    . Guillain-Barré syndrome. Lancet 1998;352:635–41 doi:10.1016/S0140-6736(97)12308-X pmid:9746040

    CrossRefPubMedWeb of Science